Cargando…

Anaplastic large cell lymphoma, with 1,25(OH)((2))D((3))-mediated hypercalcemia: A case report

Hypercalcemia due to malignant tumors including malignant lymphomas is relatively common. Among cancer patients with hypercalcemia, humoral hypercalcemia of malignancy is the most common and accounts for about 80% of all cases with hypercalcemia. 1,25-dihydroxyvitamin D((3))(1,25(OH)((2))D((3)))-med...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitobe, Masaki, Kawamoto, Keisuke, Suzuki, Takaharu, Kiryu, Maiko, Nanba, Ayako, Suwabe, Tatsuya, Tanaka, Tomoyuki, Fuse, Kyoko, Shibasaki, Yasuhiko, Masuko, Masayoshi, Miyoshi, Hiroaki, Ohshima, Koichi, Sone, Hirohito, Takizawa, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JSLRT 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528141/ https://www.ncbi.nlm.nih.gov/pubmed/30918141 http://dx.doi.org/10.3960/jslrt.18033

Ejemplares similares

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction
por: Mitobe, Masaki, et al.
Publicado: (2021)

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review
por: Katagiri, Takayuki, et al.
Publicado: (2017)

Hypertrophic pachymeningitis associated with myelodysplastic syndrome
por: Kaihatsu, Akane, et al.
Publicado: (2020)

Cladribine treatment for Erdheim–Chester disease involving the central nervous system and concomitant polycythemia vera: A case report
por: Tamura, Suguru, et al.
Publicado: (2018)

Genetic manipulation resulting in decreased donor chondroitin sulfate synthesis mitigates hepatic GVHD via suppression of T cell activity
por: Tamura, Suguru, et al.
Publicado: (2023)

Patient‐based prediction algorithm of relapse after allo‐HSCT for acute Leukemia and its usefulness in the decision‐making process using a machine learning approach
por: Fuse, Kyoko, et al.
Publicado: (2019)

P1374: EASIX ASSESSED AT 1 YEAR AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION PREDICTS THE ONSET OF SUBSEQUENT NON-RELAPSE MORTALITY
por: Takeda, R., et al.
Publicado: (2022)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness
por: Ramakrishnan, Swathi, et al.
Publicado: (2019)

MON-374 Management of 1,25-dihydroxyvitamin D (1,25-OHD) Mediated Hypercalcemia of Unknown Etiology
por: Menon, Sruthi, et al.
Publicado: (2020)

Functional dissection of hematopoietic stem cell populations with a stemness-monitoring system based on NS-GFP transgene expression
por: Ali, Mohamed A. E., et al.
Publicado: (2017)

Without 1α-hydroxylation, the gene expression profile of 25(OH)D(3) treatment overlaps deeply with that of 1,25(OH)(2)D(3) in prostate cancer cells
por: Susa, Takao, et al.
Publicado: (2018)

A rare presentation of anaplastic large cell lymphoma as a cavitary pulmonary mass with hypercalcemia
por: Chen, Hsu‐Yuan, et al.
Publicado: (2022)

Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)

1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma
por: Rodríguez-Gutiérrez, René, et al.
Publicado: (2014)

Severe Hypercalcemia From Inhalation Pneumonitis via Activation of 1,25 Dihydroxyvitamin D
por: Rosenstein, Kyle, et al.
Publicado: (2022)

Clopidogrel-induced Eosinophilia with Hypercalcemia
por: Yamada, Kazuhiro, et al.
Publicado: (2022)

Vitamin D and 1,25(OH)(2)D Regulation of T cells
por: Cantorna, Margherita T., et al.
Publicado: (2015)

1-25OH(2)D Mediated Hypercalcemia Secondary to DISR From Immune Checkpoint Inhibitors
por: Disanti, Domenic, et al.
Publicado: (2021)

Hypercalcemia Due to Paraneoplastic Production of 1,25- Dihydroxyvitamin D in a Young Female with Dysgerminoma
por: Iqbal, Iqra, et al.
Publicado: (2019)

Psychosis in a primary hyperparathyroidism patient with mild hypercalcemia: A case report
por: Otsuki, Koji, et al.
Publicado: (2021)

Textiloma-Induced 1,25-Dihydroxyvitamin D–Mediated Hypercalcemia: A Case Report and Literature Study
por: de Bellefroid, Julie, et al.
Publicado: (2019)

Hypercalcemia Owing to Overproduction of 1,25-Dihydroxyvitamin D(3) in Fetal Lung Adenocarcinoma: Case Report
por: Saito, Tomohito, et al.
Publicado: (2021)

Hypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in Sarcoma
por: Kim, Dong Won, et al.
Publicado: (2021)

SAT240 Recurrent Hypercalcemia Due To 1,25 Dihydroxy Vitamin D Elevation Of Unclear Etiology
por: Javvaji, Abhiram, et al.
Publicado: (2023)

25(OH)D and 1,25(OH)D vitamin D fails to predict sepsis and mortality in a prospective cohort study
por: Ratzinger, Franz, et al.
Publicado: (2017)

Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
por: Vlot, Mariska C, et al.
Publicado: (2019)

1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)(2)D(3) in NSCLC Treatment
por: Upadhyay, Santosh Kumar, et al.
Publicado: (2013)

The metabolism of 1,25(OH)(2)D(3) in clinical and experimental kidney disease
por: Turner, Mandy E., et al.
Publicado: (2022)

ODP079 BCG-Osis, a Rare Cause of 1,25 Hydroxy Vitamin D Mediated Hypercalcemia
por: Azim, Sidra, et al.
Publicado: (2022)

Altered microbiota by a high-fat diet accelerates lethal myeloid hematopoiesis associated with systemic SOCS3 deficiency
por: Cho, Kaori, et al.
Publicado: (2021)

Antidepressants differentially related to 1,25-(OH)(2) vitamin D(3) and 25-(OH) vitamin D(3) in late-life depression
por: Oude Voshaar, R C, et al.
Publicado: (2014)

Does Sevelamer Hydrochloride (Renagel) Influence 25(Oh)D3 and 1,25(Oh)2D3 Level in Haemodialysis Patients?
por: Strózecki, Pawel, et al.
Publicado: (2005)

25(OH)D(3) and 1.25(OH)(2)D(3) inhibits TNF-α expression in human monocyte derived macrophages
por: Rafique, Aisha, et al.
Publicado: (2019)

MON-LB74 The Problem of Measuring 1,25(OH)2 Vitamin D in Patients With High Levels of 25(OH) Vitamin D
por: Vieira, Jose Gilberto, et al.
Publicado: (2020)

Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
por: Ogura, Hiromu, et al.
Publicado: (2021)

25(OH)D-but not 1,25(OH)(2)D–Is an independent risk factor predicting graft loss in stable kidney transplant recipients
por: Zeng, Shufei, et al.
Publicado: (2023)

Vitamin D (1,25(OH)(2)D3) induces α-1-antitrypsin synthesis by CD4(+) T cells, which is required for 1,25(OH)(2)D3-driven IL-10
por: Dimeloe, Sarah, et al.
Publicado: (2019)

(125)I Seed Brachytherapy for Refractory Loco-Regional Recurrence of Non-Anaplastic Thyroid Cancer
por: Yu, Huimin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fu0kehdes26c27s3mtc2ffrth6